Obexelimab is an investigational, bifunctional monoclonal antibody designed to inhibit B cells without depleting them.
Dual Target: Binds simultaneously to CD19 on B cells and the inhibitory receptor FcγRIIb.
Modulates and inhibits B-cell activity, autoantibody production, and proliferation rather than destroying the cells.
Given as an at-home subcutaneous (under the skin) self-injection.
IgG4-Related Disease (IgG4-RD): Evaluated in the positive Phase 3 INDIGO Trial which met its primary endpoint of significantly reducing disease flare risks.
Systemic Lupus Erythematosus (SLE): Being studied in clinical trials.
Multiple Sclerosis (MS): Evaluated in a trial for relapsing multiple sclerosis.
Views: 0